Skip to main content

Correction: New clinical application prospects of artemisinin and its derivatives: a scoping review

The Original Article was published on 11 December 2023

Correction: Infectious Diseases of Poverty (2023) 12:115 https://doi.org/10.1186/s40249-023-01152-6


Following publication of the original article [1], the authors reported that the below two corrections should be made in the original article.

  1. 1.

    The sentence “safe in pink, effective in blue and invalid in green” in figure legend of Fig. 3c should be updated to “safe in pink, effective in green and invalid in yellow”.

The full correct legend of Fig. 3 should read:

a Distribution of potential clinical applications of artemisinin and its derivatives. b Word cloud of research results on efficacy/safety for diseases (due to the excessive number of studies on schistosomiasis control, the image is not shown in this figure). The graph was based on the frequency of clinical studies of artemisinin and its derivatives in the treatment of different diseases. c Research status on the efficacy and safety of artemisinin and its derivatives for potential clinical applications. The upper semicircle represents the research results, and the lower semicircle represents the field of disease. Different colors are used to distinguish the research results, that is, safe in pink, effective in green and invalid in yellow. The width of the string is based on the number of studies that have corresponding results in this field.

  1. 2.

    Author Dan Hu is removed from the author list due to personal issues.

The correct Author Contribution section should read:

YH conceived the research proposal and guided the overall study. YY, GL, YH and MX screened the literature, extracted research information and resolved the disputes. YY and GL drafted the manuscript. MX and YH critically reviewed the manuscript. All authors read and approved the final manuscript.

The original article [1] has been updated.

Reference

  1. Huang Y, Yang Y, Liu G, Xu M. New clinical application prospects of artemisinin and its derivatives: a scoping review. Infect Dis Poverty. 2023;12:115. https://doi.org/10.1186/s40249-023-01152-6.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yangmu Huang.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Y., Yang, Y., Liu, G. et al. Correction: New clinical application prospects of artemisinin and its derivatives: a scoping review. Infect Dis Poverty 13, 14 (2024). https://doi.org/10.1186/s40249-024-01180-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s40249-024-01180-w